Sarepta Therapeutics (NASDAQ:SRPT) Rating Increased to Neutral at HC Wainwright

HC Wainwright upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from a sell rating to a neutral rating in a research report sent to investors on Wednesday, MarketBeat Ratings reports. They currently have $75.00 price target on the biotechnology company’s stock.

Other equities research analysts have also issued reports about the stock. Scotiabank lowered their price target on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a report on Thursday, March 20th. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating for the company in a report on Wednesday, March 19th. Royal Bank of Canada downgraded Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their price target for the company from $161.00 to $87.00 in a report on Monday, March 31st. Needham & Company LLC reiterated a “buy” rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $163.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Six analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $163.18.

Sarepta Therapeutics Price Performance

Shares of Sarepta Therapeutics stock opened at $54.43 on Wednesday. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics has a one year low of $54.26 and a one year high of $173.25. The business’s 50 day simple moving average is $96.95 and its two-hundred day simple moving average is $113.78. The stock has a market capitalization of $5.28 billion, a P/E ratio of 43.54 and a beta of 0.79.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in SRPT. Manchester Capital Management LLC boosted its stake in Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 156 shares in the last quarter. Sunbelt Securities Inc. boosted its position in shares of Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 232 shares during the last quarter. Newbridge Financial Services Group Inc. purchased a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at $36,000. Finally, Steward Partners Investment Advisory LLC increased its holdings in Sarepta Therapeutics by 164.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock worth $38,000 after buying an additional 194 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.